A multinational report on SARS-CoV-2 infection outcomes in people with CF and Aspergillus infection or ABPA
<p><strong>Background:</strong> Aspergillus infection is known to be associated with worse respiratory outcomes in people with CF (pwCF) and is a well-recognised complication of severe SARS-CoV-2 infection. The aim of this observational cross-sectional study was to examine the asso...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2023
|
| _version_ | 1817931338392535040 |
|---|---|
| author | Bradbury, JD Chesshyre, E Orenti, A Jung, A Warris, A European Cystic Fibrosis COVID project group |
| author_facet | Bradbury, JD Chesshyre, E Orenti, A Jung, A Warris, A European Cystic Fibrosis COVID project group |
| author_sort | Bradbury, JD |
| collection | OXFORD |
| description | <p><strong>Background:</strong> Aspergillus infection is known to be associated with worse respiratory outcomes in people with CF (pwCF) and is a well-recognised complication of severe SARS-CoV-2 infection. The aim of this observational cross-sectional study was to examine the association of pre-existing Aspergillus infection and/or allergic bronchopulmonary aspergillosis (ABPA) in pwCF and severity of COVID-19.</p>
<br>
<p><strong>Methods:</strong> Data on SARS-CoV-2 infections in pwCF from January 2020 to June 2021 were collected by the European Cystic Fibrosis Society Patient Registry. The primary outcome was COVID-19 severity measured by hospitalisation comparing those with Aspergillus infection and/or ABPA in the 12 months preceding COVID-19 and those without.</p>
<br>
<p><strong>Results:</strong> In total, 1095 pwCF were diagnosed with SARS-CoV-2 and information on pre-existing Aspergillus/ABPA status was available from 807. PwCF and SARS-CoV-2 in the Aspergillus/ABPA group (n = 153), in comparison to the non-Aspergillus/ABPA group (n = 654), were more likely to be hospitalised (adjusted OR 1.79 (1.19 to 2.85); p = 0.005) and their disease course was more likely to be complicated by sepsis (adjusted OR 7.78 (1.78 to 49.43); p = 0.008). The association with hospital admission was no longer significant after excluding patients with ABPA. Secondary analysis comparing pwCF who received antifungal treatment (n = 18), versus those who did not (n = 474) during COVID-19, showed a higher rate of hospitalisation (p < 0.001); intensive care unit admission (p < 0.001), and requirement for invasive ventilation (p < 0.001) in the antifungal treated group.</p>
<br>
<p><strong>Conclusion:</strong> We show that pre-existing Aspergillus/ABPA is associated with increased rates of hospitalisation and sepsis during COVID-19 in pwCF.</p> |
| first_indexed | 2024-12-09T03:20:26Z |
| format | Journal article |
| id | oxford-uuid:89e55b63-93d1-44f9-8a4f-6e8a60d9136c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-12-09T03:20:26Z |
| publishDate | 2023 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:89e55b63-93d1-44f9-8a4f-6e8a60d9136c2024-11-07T15:25:54ZA multinational report on SARS-CoV-2 infection outcomes in people with CF and Aspergillus infection or ABPAJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:89e55b63-93d1-44f9-8a4f-6e8a60d9136cEnglishSymplectic ElementsElsevier2023Bradbury, JDChesshyre, EOrenti, AJung, AWarris, AEuropean Cystic Fibrosis COVID project group<p><strong>Background:</strong> Aspergillus infection is known to be associated with worse respiratory outcomes in people with CF (pwCF) and is a well-recognised complication of severe SARS-CoV-2 infection. The aim of this observational cross-sectional study was to examine the association of pre-existing Aspergillus infection and/or allergic bronchopulmonary aspergillosis (ABPA) in pwCF and severity of COVID-19.</p> <br> <p><strong>Methods:</strong> Data on SARS-CoV-2 infections in pwCF from January 2020 to June 2021 were collected by the European Cystic Fibrosis Society Patient Registry. The primary outcome was COVID-19 severity measured by hospitalisation comparing those with Aspergillus infection and/or ABPA in the 12 months preceding COVID-19 and those without.</p> <br> <p><strong>Results:</strong> In total, 1095 pwCF were diagnosed with SARS-CoV-2 and information on pre-existing Aspergillus/ABPA status was available from 807. PwCF and SARS-CoV-2 in the Aspergillus/ABPA group (n = 153), in comparison to the non-Aspergillus/ABPA group (n = 654), were more likely to be hospitalised (adjusted OR 1.79 (1.19 to 2.85); p = 0.005) and their disease course was more likely to be complicated by sepsis (adjusted OR 7.78 (1.78 to 49.43); p = 0.008). The association with hospital admission was no longer significant after excluding patients with ABPA. Secondary analysis comparing pwCF who received antifungal treatment (n = 18), versus those who did not (n = 474) during COVID-19, showed a higher rate of hospitalisation (p < 0.001); intensive care unit admission (p < 0.001), and requirement for invasive ventilation (p < 0.001) in the antifungal treated group.</p> <br> <p><strong>Conclusion:</strong> We show that pre-existing Aspergillus/ABPA is associated with increased rates of hospitalisation and sepsis during COVID-19 in pwCF.</p> |
| spellingShingle | Bradbury, JD Chesshyre, E Orenti, A Jung, A Warris, A European Cystic Fibrosis COVID project group A multinational report on SARS-CoV-2 infection outcomes in people with CF and Aspergillus infection or ABPA |
| title | A multinational report on SARS-CoV-2 infection outcomes in people with CF and Aspergillus infection or ABPA |
| title_full | A multinational report on SARS-CoV-2 infection outcomes in people with CF and Aspergillus infection or ABPA |
| title_fullStr | A multinational report on SARS-CoV-2 infection outcomes in people with CF and Aspergillus infection or ABPA |
| title_full_unstemmed | A multinational report on SARS-CoV-2 infection outcomes in people with CF and Aspergillus infection or ABPA |
| title_short | A multinational report on SARS-CoV-2 infection outcomes in people with CF and Aspergillus infection or ABPA |
| title_sort | multinational report on sars cov 2 infection outcomes in people with cf and aspergillus infection or abpa |
| work_keys_str_mv | AT bradburyjd amultinationalreportonsarscov2infectionoutcomesinpeoplewithcfandaspergillusinfectionorabpa AT chesshyree amultinationalreportonsarscov2infectionoutcomesinpeoplewithcfandaspergillusinfectionorabpa AT orentia amultinationalreportonsarscov2infectionoutcomesinpeoplewithcfandaspergillusinfectionorabpa AT junga amultinationalreportonsarscov2infectionoutcomesinpeoplewithcfandaspergillusinfectionorabpa AT warrisa amultinationalreportonsarscov2infectionoutcomesinpeoplewithcfandaspergillusinfectionorabpa AT europeancysticfibrosiscovidprojectgroup amultinationalreportonsarscov2infectionoutcomesinpeoplewithcfandaspergillusinfectionorabpa AT bradburyjd multinationalreportonsarscov2infectionoutcomesinpeoplewithcfandaspergillusinfectionorabpa AT chesshyree multinationalreportonsarscov2infectionoutcomesinpeoplewithcfandaspergillusinfectionorabpa AT orentia multinationalreportonsarscov2infectionoutcomesinpeoplewithcfandaspergillusinfectionorabpa AT junga multinationalreportonsarscov2infectionoutcomesinpeoplewithcfandaspergillusinfectionorabpa AT warrisa multinationalreportonsarscov2infectionoutcomesinpeoplewithcfandaspergillusinfectionorabpa AT europeancysticfibrosiscovidprojectgroup multinationalreportonsarscov2infectionoutcomesinpeoplewithcfandaspergillusinfectionorabpa |